You are hereInclusion / Exclusion Criteria

Inclusion / Exclusion Criteria

Inclusion Criteria

  • Neurologic deficit (based on history or  exam) attributed to focal brain ischemia and EITHER:
    • High risk TIA: Complete resolution of the deficit at the time of  randomization AND ABCD2 score >4


    • Minor ischemic stroke:  residual deficit with NIHSS< 3 at the time of randomization.
  • Ability to randomize within 12 hours of time last known free of new ischemic symptoms.
  • Head CT or MRI ruling out hemorrhage or other pathology, such as vascular malformation, tumor, or abscess, that could explain symptoms or contraindicate therapy.
  • Ability to tolerate aspirin at a dose of 50-325 mg/day.

Exclusion Criteria

    • Age <18 years
    • TIA symptoms limited to isolated numbness, isolated visual changes, or isolated dizziness/vertigo.
    • In the judgment of the treating physician, a candidate for thrombolysis endarterectomy of endovascular intervention.
    • Receipt of any intravenous or intra-arterial thrombolysis within 1 week prior to index event.
    • Gastrointestinal bleed or major surgery within 3 months prior to index event.
    • History of non-traumatic intracranial hemorrhage.
    • Clear indication for anticoagulation (e.g., warfarin, heparin) anticipated during the study period (atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state).
    • Qualifying  ischemic event induced by angiography or surgery.
    • Severe non-cardiovascular comorbidity with life expectancy <3 months.
    • Contraindication to clopidogrel or aspirin:
      • Known allergy
      • Severe renal (serum creatinine >2 mg/dL) or hepatic insufficiency (prior or concurrent diagnosis, with INR>1.5, or any resultant complication, such as variceal bleeding, encephalopathy, or icterus)
      • Hemostatic disorder or systemic bleeding in the past 3 months
      • Current thrombocytopenia (platelet count <100 x109/l) or neutropenia/granulocytopenia (<1 x109/l)
      • History of drug-induced hematologic or hepatic abnormalities
    • Anticipated requirement for long-term (>7 day) nonstudy antiplatelet drugs (eg, dipyridamole, clopidogrel, ticlopidine), or NSAIDs affecting platelet function (such as prior vascular stent or arthritis).
    • Not willing or able to discontinue prohibited concomitant medications.
    • Inability to swallow medications.
    • At risk for pregnancy:  premenopausal or postmenopausal woman within 12 months of last menses without a negative pregnancy test or not committing to adequate birth control (e.g., oral contraceptive, two methods of barrier birth control, or abstinence).
    • Unavailability for follow-up.
    • Inability to provide informed consent.
    • Other neurological conditions that would complicate assessment of outcomes during follow-up.
    • Ongoing treatment in another study of an investigational therapy, or treatment in such a study within the last 7 days.